Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry
- PMID: 35895855
- DOI: 10.1111/bjd.21794
Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry
Abstract
This interim analysis from the atopic dermatitis registry TREATgermany shows robust long-term efficacy, favourable safety and high persistence of dupilumab under real life conditions.
© 2022 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
References
-
- Simpson EL, Bieber T, Guttman-Yassky E et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375:2335-48.
-
- Ratchataswan T, Banzon TM, Thyssen JP et al. Biologics for treatment of atopic dermatitis: current status and future prospect. J Allergy Clin Immunol Pract 2021; 9:1053-65.
-
- Stölzl D, Weidinger S, Drerup K. A new era has begun: treatment of atopic dermatitis with biologics. Allergol Select 2021; 5:265-73.
-
- Drucker AM, Morra DE, Prieto-Merino D et al. Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis. JAMA Dermatol 2022; 158:523-32.
-
- Schmitt J, Abraham S, Trautmann F et al. Usage and effectiveness of systemic treatments in adults with severe atopic eczema: first results of the German Atopic Eczema Registry TREATgermany. J Dtsch Dermatol Ges 2017; 15:49-59.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
